Abbisko Therapeutics of Shanghai completed a $123 million Series D financing to develop its portfolio of 12 oncology and one diabetes candidates that it hopes will be best-in-class treatments. The company's two lead products are a small molecule FGFR4 inhibitor for hepatocellular carcinoma and a CSF1R inhibitor for solid tumors. The D round was led by The Carlyle Group, with leading investors Warburg Pincus, OrbiMed, Lake Bleu Capital and one unnamed firm. More details.... Share this with colleagues: // //